Mainz Biomed B.V.
MYNZ
$-0.14
Change (1 day)
$7.95
Year High
$0.18
Year Low
Categories
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
P/B ratio for Mainz Biomed B.V. (MYNZ)
P/B ratio as of 2023: 5.80
According to Mainz Biomed B.V.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.80. At the end of 2022 the company had a P/B ratio of 7.13.
P/B ratio history for Mainz Biomed B.V. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 5.80 |
| 2022 | 7.13 |
| 2021 | 11.78 |
| 2020 | -20.43 |
| 2019 | -59.98 |